EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach

Edda Gomez-Panzani, Chang, Joaquim Ramis, Landolfi, Bert Bakker

Research and Reports in Endocrine Disorders · 2012

DOI: 10.2147/rred.s38149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research and Reports in Endocrine Disorders, 2012. Verfasst von Edda Gomez-Panzani und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gomez-Panzani, E., Chang, Ramis, J., Landolfi, & Bakker, B. (2012). Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Research and Reports in Endocrine Disorders. https://doi.org/10.2147/rred.s38149

Vancouver

Gomez-Panzani E, Chang, Ramis J, Landolfi, Bakker B. Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach. Research and Reports in Endocrine Disorders. 2012. doi:10.2147/rred.s38149

BibTeX
@article{GomezPanzani2012,
  author = {Gomez-Panzani, Edda and Chang and Ramis, Joaquim and Landolfi and Bakker, Bert},
  title = {Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach},
  journal = {Research and Reports in Endocrine Disorders},
  year = {2012},
  doi = {10.2147/rred.s38149}
}
Kostenlos starten →